Novartis has agreed to acquire a subsidiary of IFM Therapeutics for up to $1.575 billion, IFM said today, in a deal that will expand the pharma giant’s pipeline with one clinical and two pre-clinical ...

Novartis AGNVS announced that it will acquire IFM Tre, a subsidiary of IFM Therapeutics LLC. The acquisition will add a broad portfolio of immunomodulatory medicines, focused on developing ...

Novartis will team up with a subsidiary of IFM Therapeutics to develop immunotherapies designed to fight inflammatory and autoimmune diseases by inhibiting the cGAS/STING pathway. Mutations activating ...

Today Novartis announced the acquisition of IFM Therapeutics’ portfolio of NLRP3 antagonists, via the purchase of IFM Tre, a subsidiary of IFM (here, here). These immunomodulatory medicines target the ...

FEDERAL WAY, Wash.--(BUSINESS WIRE)--The Institute for Functional Medicine’s (IFM) Governing Board of Directors (BOD) is pleased to announce reappointments to the BOD and slate of officers. IFM BOD ...

TREDYFFRIN >> Reports of the demise of the American manufacturing sector have been greatly exaggerated. So says Roger Varma, CEO of ifm efector USA, who repeated the mantra Tuesday during a ribbon ...